Navigation Links
Sequent Medical, Inc. Awarded U.S. Patent For Innovative Implant Designs Using Composite Wire Technology

ALISO VIEJO, Calif., July 14, 2015 /PRNewswire/ -- Sequent Medical announced today the grant by the U.S. Patent and Trademark Office of Patent No. 9,078,658, entitled "Filamentary Devices for Treatment of Vascular Defects."

This new patent – the eighth U.S. Patent granted to Sequent – covers many versions of Sequent's WEB™ Aneurysm Embolization System.  WEB is a braided implant that includes composite drawn filled tube wires, i.e., an external nitinol tube and a highly radiopaque material disposed within the tube.  Sequent's WEB Aneurysm Embolization System devices utilize this technology for Enhanced Visualization ("EV") while preserving desired mechanical properties.  WEB is braided from numerous wires, which in some cases are less than one-quarter of the diameter of a human hair.

As previously reported, the company has developed and introduced in Europe EV versions of WEB in single-layer WEB SL and SLS configurations.  In the United States, enrollment in an Investigational Device Exemption ("IDE") clinical study called WEB-IT is underway; WEB EV designs are now being implanted in the study.

"We are pleased to have achieved this important milestone in our ongoing efforts to develop our intellectual property portfolio," said Tom Wilder, President and Chief Executive Officer.  "Improving the visualization of WEB proved to be a significant engineering challenge.  EV technology is the latest demonstration of Sequent's robust innovation capability, and further extends our leadership of the intrasaccular flow disruption category.  The utility of Sequent's proprietary technology extends beyond the neurovascular field, and has the potential to address a number of unmet clinical needs."

About Sequent Medical, Inc.
Founded in 2007, Sequent Medical, Inc. ( is a privately held venture backed medical device company that is dedicated to the development of innovative catheter-based neurovascular technologies.  WEB Aneurysm Embolization System and VIA® Microcatheter have both received the CE mark.  The VIA has been cleared for commercial use in the United States.  In the United States, WEB is an investigational device limited by United States law to investigational use.  Sequent is headquartered in Aliso Viejo, California, and has European operations based in Bonn, Germany.

About WEB Aneurysm Embolization System
Building upon the foundation of endovascular embolic coils, WEB is an intrasaccular flow disrupter that is implanted into a ruptured or unruptured intracranial aneurysm to promote rapid, peri-procedural stasis.  WEB is based upon Sequent Medical's proprietary MicroBraid™ technology, a dense mesh constructed from a large number of extremely fine wires.  Unlike conventional medical braids, MicroBraid allows for a mix of wire diameters or materials to achieve a tailored balance of compliance, porosity and profile across device sizes.

WEB enables physicians to treat a broad range of intracranial aneurysms with the familiarity of an intrasaccular approach while using established biomaterials.  To date, WEB has been used to treat over 1,700 ruptured and unruptured aneurysms worldwide.


SOURCE Sequent Medical, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Sequent Medical nombra a Mike Kleine a su junta directiva
2. Sequent Medical beruft Mike Kleine in den Aufsichtsrat
3. Sequent Medical Appoints Mike Kleine to its Board of Directors
4. Sequent Medical Announces Presentation of Compelling Long-Term Clinical Data and Commercial Release of its Next Generation WEB Product
5. Sequent Medical Announces Approval To Utilize Latest Generation WEB Devices In U.S. IDE Study
6. Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt
7. Sequent Medical annonce le démarrage dune étude IDE pour le système WEB dembolisation des anévrismes
8. Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System
9. Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark
10. New Data Shows Cognitive Impairment Precedes and Predicts Subsequent Functional Impairment in Patients with Mild Alzheimers Disease
11. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
Post Your Comments:
(Date:9/18/2019)... N.J. (PRWEB) , ... September 18, 2019 , ... The ... need. They all attended the Youth Consultation Services Foundation (YCS) in Hackensack , ... They also spent time with the children and threw them a pizza party and ...
(Date:9/17/2019)... ... September 17, 2019 , ... AssuriCare LLC , ... RegistryConnect , the first and most compliant online management platform developed for ... recording, client and caregiver relationship management. RegistryConnect is available only to home care ...
(Date:9/17/2019)... ... September 17, 2019 , ... Today, in partnership with Lehman ... and consent with student and faculty from The City University of New York ... Ramirez, MPH; Elise Schuster, MPH; Raffaele M. Bernardo, DO, FACP, AAHIVS and Stuart ...
Breaking Medicine Technology:
(Date:9/18/2019)... Ore. (PRWEB) , ... September 18, 2019 , ... A new study by BestPlaces looks ... . Same-sex marriage is the only Federally-mandated right, so other related rights vary widely across ... Conversion Therapy (trying to change an individual's sexual orientation) , Employment , ...
(Date:9/17/2019)... ... September 17, 2019 , ... ... Keflezighi and the American Heart Association (AHA)-San Diego Chapter to raise awareness of ... Stroke Walk on Saturday, September 21 in Balboa Park alongside National University System ...
(Date:9/17/2019)... , ... September 17, 2019 , ... ... initiative contributing to the long-term health of canines – specifically golden retrievers - ... Golden Retrievers will die from cancer – one out of five retrievers in ...
(Date:9/17/2019)... , ... September 17, 2019 , ... ... join the largest accountable care organization (ACO) in the country, the company announced ... groundbreaking collaboration to improve care quality and increase cost efficiency. This opportunity is ...
(Date:9/17/2019)... ... September 17, 2019 , ... Dr. Perry ... has been certified by the American Academy of Facial Esthetics (AAFE) to administer ... wide range of orofacial conditions such as tooth clenching and grinding, tongue tension, ...
Breaking Medicine News(10 mins):